MA30164B1 - Nouvelle forme cristalline de la vinflunine - Google Patents

Nouvelle forme cristalline de la vinflunine

Info

Publication number
MA30164B1
MA30164B1 MA31122A MA31122A MA30164B1 MA 30164 B1 MA30164 B1 MA 30164B1 MA 31122 A MA31122 A MA 31122A MA 31122 A MA31122 A MA 31122A MA 30164 B1 MA30164 B1 MA 30164B1
Authority
MA
Morocco
Prior art keywords
vinflunine
crystalline form
new crystalline
new
cancers
Prior art date
Application number
MA31122A
Other languages
English (en)
Inventor
Jean-Louis Maurel
Richard Pena
Jean-Paul Ribet
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA30164B1 publication Critical patent/MA30164B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nouvelle forme cristalline de la vinflunine. DEPOSANTS : PIERRE FABRE MEDICAMENT La présente invention concerne une nouvelle forme cristalline de la vinflunine, son procédé d'obtention, ainsi que ses utilisations dans le domaine thérapeutique, en particulier pour le traitement des cancers.
MA31122A 2005-12-20 2008-07-16 Nouvelle forme cristalline de la vinflunine MA30164B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512942A FR2894966B1 (fr) 2005-12-20 2005-12-20 Nouvelle forme cristalline de la vinflunine
US77420106P 2006-02-17 2006-02-17

Publications (1)

Publication Number Publication Date
MA30164B1 true MA30164B1 (fr) 2009-01-02

Family

ID=36169082

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31122A MA30164B1 (fr) 2005-12-20 2008-07-16 Nouvelle forme cristalline de la vinflunine

Country Status (20)

Country Link
US (1) US20090247564A1 (fr)
EP (1) EP1971613A1 (fr)
JP (1) JP2009519996A (fr)
KR (1) KR101437696B1 (fr)
CN (1) CN101331139A (fr)
AR (1) AR058704A1 (fr)
AU (1) AU2006328560B2 (fr)
BR (1) BRPI0620143A2 (fr)
CA (1) CA2633769A1 (fr)
FR (1) FR2894966B1 (fr)
IL (1) IL192249A0 (fr)
MA (1) MA30164B1 (fr)
NO (1) NO20083186L (fr)
NZ (1) NZ569884A (fr)
RU (1) RU2426735C2 (fr)
TN (1) TNSN08268A1 (fr)
TW (1) TW200733962A (fr)
UA (1) UA91581C2 (fr)
WO (1) WO2007071648A1 (fr)
ZA (1) ZA200806135B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912406B1 (fr) 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US20190307741A1 (en) * 2016-07-06 2019-10-10 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
IL308577A (en) * 2021-05-27 2024-01-01 Metro Int Biotech Llc Crystalline solids of nicotinic acid mononucleotides and their esters and methods for their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2154314A1 (en) * 1971-09-28 1973-05-11 Richter Gedeon Vegyeszet Vinca rosea alkaloids - vinblastine, vinleurosine and vincristine selective isolation
JPS5283900A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Novel acidic and ester derivatives of vinblastine vincrystine and roylocidine
HU173379B (hu) * 1976-02-13 1979-04-28 Richter Gedeon Vegyeszet Sposob poluchenija 4-dezacetoksi-vinblastina i kislo-additivnykh solejj
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
GB2012260B (en) * 1977-11-07 1982-11-03 Lilly Co Eli 4-desacetoxy 4 hydroxyindole dihydroindoles pharmaceutical formulations containing them and their use as antimitotic agents
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2761990B1 (fr) 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
AR024852A1 (es) * 2000-01-12 2002-10-30 Eriochem Sa Procedimiento para la produccion de ditartrato de 5'-nor-anhidrovinblastina a partir de especies vegetales del genero catharanthus y procedimiento a escala industrial.
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it

Also Published As

Publication number Publication date
BRPI0620143A2 (pt) 2011-11-01
AR058704A1 (es) 2008-02-20
RU2426735C2 (ru) 2011-08-20
JP2009519996A (ja) 2009-05-21
KR101437696B1 (ko) 2014-09-03
TNSN08268A1 (en) 2009-10-30
AU2006328560B2 (en) 2012-03-22
FR2894966A1 (fr) 2007-06-22
RU2008128317A (ru) 2010-01-27
CA2633769A1 (fr) 2007-06-28
KR20080077696A (ko) 2008-08-25
WO2007071648A1 (fr) 2007-06-28
CN101331139A (zh) 2008-12-24
NZ569884A (en) 2011-03-31
FR2894966B1 (fr) 2008-03-14
AU2006328560A1 (en) 2007-06-28
NO20083186L (no) 2008-09-11
UA91581C2 (en) 2010-08-10
EP1971613A1 (fr) 2008-09-24
US20090247564A1 (en) 2009-10-01
ZA200806135B (en) 2009-08-26
IL192249A0 (en) 2008-12-29
TW200733962A (en) 2007-09-16

Similar Documents

Publication Publication Date Title
FR2889526B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MA29634B1 (fr) Heterocycles condenses avec la 1,4-dihydropyridine, procede pour preparer ceux-ci, utilisation et compositions contenant ceux-ci
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MA33737B1 (fr) Dérivés de glycoside et utilisations de ceux-ci
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
DOP2003000632A (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
HUP0303526A2 (hu) Azetidinon-intermedier vegyületek enantioszelektiv szintézise
MA33368B1 (fr) Préparation de chlorhydrate de nalmefene à partir de naltrexone
DE602004014361D1 (de) Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen
MY142988A (en) Novel aminobenzophenone compounds
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
TNSN08428A1 (fr) NOUVELLE FORME d'ADMINISTRATION DU RACECADOTRIL
MA31198B1 (fr) Nouvelle forme dosifiee
TW200630374A (en) Thiazolyldihydroindazoles
MA30164B1 (fr) Nouvelle forme cristalline de la vinflunine
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
MA30039B1 (fr) Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20055741L (no) Nye kjemiske forbindelser
EP1602672A4 (fr) Copolymere de propylene, composition le contenant et procede de production
DE502006003215D1 (de) Rmazeutische zusammensetzung sowie verwendung von calcium-chelatbildner und ophthalmologisch verträglichem viskositätsregler
MA34580B1 (fr) Valsartan hautement cristallin